These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1014 related items for PubMed ID: 11213385

  • 1. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S, Oprisiu R, Benamar L, Said S, Tataru Albu A, Arsenescu I, el Esper N, Morinière P, Fournier A.
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [Abstract] [Full Text] [Related]

  • 2. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C, Bako G, Oprisiu R, Georgita A, Presne C, Sarraj A, Morinière P, el Esper N, Fournier A.
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [Abstract] [Full Text] [Related]

  • 3. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.
    Nephron; 1995 Nov; 71(3):254-83. PubMed ID: 8569975
    [Abstract] [Full Text] [Related]

  • 6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Nov; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 7. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A, Morinière P, Ben Hamida F, el Esjer N, Shenovda M, Ghazali A, Bouzernidj M, Achard JM, Westeel PF.
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [Abstract] [Full Text] [Related]

  • 8. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R, Bolosiu H, Boca I, Theodoru C, Elefterescu R, Brazier M, el Esper I, Leflon P, Ledeme C, Fournier A, Heinze V.
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [Abstract] [Full Text] [Related]

  • 9. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
    Fournier A, Morinière P, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.
    Nephrologie; 1995 Mar; 16(2):165-90. PubMed ID: 7753302
    [Abstract] [Full Text] [Related]

  • 10. Adynamic bone disease in patients with uremia.
    Fournier A, Yverneau PH, Hué P, Said S, Hamdini N, Eldin HM, Mohageb S, Oprisiu R, Marie A, Solal ME.
    Curr Opin Nephrol Hypertens; 1994 Jul; 3(4):396-410. PubMed ID: 8076143
    [Abstract] [Full Text] [Related]

  • 11. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T, Ritz E, Passlick-Deetjen J.
    Perit Dial Int; 1996 Jul; 16(3):260-8. PubMed ID: 8761540
    [Abstract] [Full Text] [Related]

  • 12. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F, Ghazali A, Boudzernidj M, Amar M, Morinière P, Westeel P, Fournier A.
    Ann Endocrinol (Paris); 1994 Jul; 55(5):147-58. PubMed ID: 7857079
    [Abstract] [Full Text] [Related]

  • 13. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Jul; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Jul; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 15. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C, Armas JR, Palma A.
    Nefrologia; 2001 Jul; 21(2):174-81. PubMed ID: 11464651
    [Abstract] [Full Text] [Related]

  • 16. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis.
    Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A.
    Nephrol Dial Transplant; 1994 Jul; 9(5):517-23. PubMed ID: 7522307
    [Abstract] [Full Text] [Related]

  • 17. Prevention of renal osteodystrophy in peritoneal dialysis.
    Weinreich T.
    Kidney Int; 1998 Dec; 54(6):2226-33. PubMed ID: 9853289
    [Abstract] [Full Text] [Related]

  • 18. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U.
    Schweiz Rundsch Med Prax; 1994 Jun 14; 83(24):738-56. PubMed ID: 8023059
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for renal osteodystrophy: a multivariant analysis.
    Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D.
    J Bone Miner Res; 1995 Jan 14; 10(1):149-56. PubMed ID: 7747622
    [Abstract] [Full Text] [Related]

  • 20. [Renal osteodystrophy (1): invasive and non-invasive diagnosis of its pathologic varieties].
    Oprisiu R, Hottelart C, Ghitsu S, Said S, Westeel PF, Morinière P, el Esper N, Pruna A, Fournier A.
    Nephrologie; 2000 Jan 14; 21(5):229-37. PubMed ID: 11068772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.